Држава: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
OLANZAPINE BENZOATE
Synthon BV
5 Milligram
Tablets
2008-07-21
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Olanzapine Synthon 5 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains olanzapine benzoate equivalent to 5 mg olanzapine. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet Light yellow, round, biconvex tablets, debossed with "OPN" and “5” on one side and “bza” on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Schizophrenia: The recommended starting dose for olanzapine is 10 mg/day. Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (See section 5.1). Preventing recurrence in bipolar disorder: The recommended starting dose is 10 mg/day. For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated. During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the ra Прочитајте комплетан документ